Table 4.

Comparison of chemotherapy combinations and doses in the FAB/LMB and BFM regimens

Regimen	Phase of therapy	Chemotherapeutic agents and doses per phase, mg/m2								IT doses, n
		Cycl	VCR	P or D	Doxo	MTX	Cyta	Etop	Ifos
BFM	V	400	—	D: 40	—	—	—	—	—	1
	A	—	1.5*	D: 50	—	1000	600	200	4000	1
	B	1000	1.5*	D: 50	50	1000	—	—	—	1
	AA	—	1.5	D: 50	—	5000	600	200	4000	2†
	BB	1000	1.5	D: 50	50	5000	—	—	—	2†
	CC	—	3*	D: 100	—	—	12 000	500	—	1†
LMB	COP	300	1	P: 420	—	—	—	—	—	1†
	COPAD	1500	4	P: 360	60	—	—	—	—	0
	COPADM	1500	2	P: 300	60	3000-8000‡	—	—	—	2†
	COPADM2	3000	2	P: 300	60	8000	—	—	—	3
	CYM	—	—	—	—	3000	500	—	—	2
	CYVE	—	—	—	—	8000§	12 250	800	—	1-2§
	m1	1000	2	P: 300	60	8000	—	—	—	1
	m2	—	—	—	—	—	500	450	—	0

Cycl, cyclophosphamide; Cyta, cytarabine; D, dexamethasone; Etop, etoposide; Ifos, ifosfamide; IT, intrathecal; P, prednisone.

^*Vincristine is omitted from the BFM R1 regimen and is replaced by vindesine in the CC phase of therapy.

^†Additional IT therapy is administered to patients with CNS involvement in the BFM regimen, as well as for patients in LMB group C.

^‡Dose of MTX is 3000 mg/m² for patients in group B and 8000 mg/m² for patients in group C in LMB.

^§High-dose MTX and an additional dose of intrathecal chemotherapy is given to patients with CNS involvement during 1st CYVE phase only.